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(miRNAs) are important post-transcriptional gene expression
regulators relevant in physiological and pathological processes.
Here, we combined a high-throughput functional screening
(HTFS) platform with a library of antisense oligonucleotides
(ASOs) to systematically identify sncRNAs that affect neuronal
cell survival in basal conditions and in response to oxidative
stress (OS), a major hallmark in neurodegenerative diseases.
We considered hits commonly detected by two statistical
methods in three biological replicates. Forty-seven ASOs tar-
geting miRNAs (miRNA-ASOs) consistently decreased cell
viability under basal conditions. A total of 60 miRNA-ASOs
worsened cell viability impairment mediated by OS, with
36.6% commonly affecting cell viability under basal conditions.
In addition, 40 miRNA-ASOs significantly protected neuronal
cells from OS. In agreement with cell viability impairment,
damaging miRNA-ASOs specifically induced increased free
radical biogenesis. miRNAs targeted by the detrimental ASOs
are enriched in the fraction of miRNAs downregulated by
OS, suggesting that the miRNA expression pattern after OS
contributes to neuronal damage. The present HTFS high-
lighted potentially druggable sncRNAs. However, future
studies are needed to define the pathways by which the identi-
fied ASOs regulate cell survival and OS response and to explore
the potential of translating the current findings into clinical
applications.Received 18 January 2019; accepted 11 June 2019;
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Different classes of small non-coding RNA (sncRNA) species have
been uncovered with sequencing strategies, with many modulating
gene expression through diverse mechanisms.MicroRNAs (miRNAs)
are the best known class of sncRNAs, transcribed as long precursors
(pri-miRNAs) and processed to a mature, double-stranded, short
RNA of 20–25 nt.1 The active strand of this duplex is loaded into
the RNA-induced silencing complex (RISC), where it guides mRNA374 Molecular Therapy: Nucleic Acids Vol. 17 September 2019 ª 2019
This is an open access article under the CC BY-NC-ND license (httpdecay or inhibition of translation through incomplete base pairing
with the 30 UTR of target genes.2 Each miRNA targets hundreds of
genes, and a gene can be targeted by several miRNAs.3 We have
recently shown that the number of miRNAs is larger than antici-
pated,4 with new miRNA candidates being evolutionarily young
and overrepresented in the human brain.
Relative to other tissues, the nervous system is especially enriched in
diverse miRNAs and other types of ncRNAs of unknown function
that show specific spatial-temporal patterns of expression.5 Func-
tional studies, with special emphasis on miRNAs, have revealed
that their dynamic expression has essential roles in cell-type specifi-
cation and differentiation during development,6 but also in the
maintenance of adult post-mitotic cells. Conditional inactivation of
Dicer, the limiting enzyme of miRNA biogenesis, in specific areas
of the adult mouse brain consistently results in progressive loss of
specific types of neurons.7–9 In addition, perturbation of selective
miRNAs affects neuronal viability.10–12 Therefore, specific miRNAs
and possibly other types of sncRNAs may be particularly relevant
in preserving neuronal viability.
sncRNA expression is highly sensitive to physiological and patholog-
ical stimuli, with consequent modifications in gene expression leading
to a specific cell status. In neurodegenerative diseases, ncRNA alter-
ations occurring at prodromal phases are especially relevant, as
they may determine initial gene expression changes with pathogenic
impact. This scenario prompts the idea that the activity of specific
sncRNAs could be targeted to overcome or delay pathogenesis.The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Scheme of the Experimental Design for the HTFS
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mentary to miRNAs (miRNA-ASOs) bind with high specificity
to the target sncRNAs and inhibit their activity by impeding the
association of miRNAs with the complementary sites in the target
mRNAs, which may restore expression levels of specific genes.
miRNA-ASOs are therefore useful molecules for identifying miR-
NAs with a relevant role in neuronal maintenance. Stabilized ASOs
targeting other classes of sncRNA (sncRNA-ASOs) have the po-
tential to similarly uncover the novel bioactive species implicated
in cell survival.
High-throughput functional screenings (HTFSs) have used
miRNA-ASOs or RNA molecules designed to mimic endogenous
mature miRNA (miRNA-mimics), to identify species with an effect
in the expression of dosage-sensitive genes, in reporter assays.13,14
In addition, most HTFS analyses have evaluated the effect of a
moderate number of miRNA-mimics or -ASOs in tumorigenic
outcomes, including cell invasiveness,15 tumor cell death,16 or
cell growth.17,18 HTFS studies to generally identify sncRNAs
with a role in differentiated neuronal cell viability are missing.
In the present study, we developed a high-throughput screening
platform to evaluate the effect of 2,004 sncRNA-ASOs, targeting
miRNAs (a total of 1,954) and non-miRNA sncRNAs (a total of
50) in neuronal cell viability, under both normal and basal
conditions and following oxidative stress (OS), a major hallmark
in neurodegenerative disorders. We used a statistical scoring
method developed for high-throughput screenings to target
hits,19 a subgroup of which was confirmed by using an alternative
statistical strategy that we developed, dealing with biological
replicates. In addition, we used alternative functional approaches
to validate hits targeted by both statistical methods. Our
approach has identified a reliable group of detrimental and protec-
tive sncRNA-ASOs, which may reflect the involvement of the
targeted species in neuronal maintenance and response to stress.
Finally, we analyzed sncRNA expression dynamics after OS,
suggesting that deregulation of several sncRNA species may
contribute to neuronal dysfunction. Our data provide a large cat-
alog of sncRNA-ASOs that may be selected for pre-clinical valida-
tion in model organisms.RESULTS
HTFS Identifies Multiple miRNA-ASOs That Affect Cell Viability
and Response to MPP+ Stress
To identify sncRNAs with a role in neuronal survival, we set up
an HTFS to evaluate cell viability after inhibiting the activity of
miRNAs and other types of sncRNAs. We used a library of
locked-nucleic-acid (LNA)-modified ASOs targeting 1,954 miRNAs
and 50 sncRNAs not typified as miRNAs that our studies have
described in deep-sequencing data analysis of human brain sam-
ples20 (Table S1). The sncRNA-ASOs were individually transfected
in three independent biological replicates into SH-SY5Y cells differ-
entiated into a post-mitotic, dopaminergic phenotype, a cell model
largely used to understand the molecular bases of neuronal dysfunc-
tion.21,22 Two days after transfection, viability was determined with
WST-1 tetrazolium reagent, whose bioreduction correlates with
the number of metabolically active cells23 (Figure 1). In every plate,
we included a mock-transfected condition and a positive control of
decreased cell viability, by transfecting a sncRNA-ASO that induces
cell death.
We used two statistical approaches to identify sncRNA-ASOs
that affect neuronal cell viability. The first approach is based on the
B score,19 a powerful method designed for plate-based assays that de-
tects hits under the assumption that the vast majority of the screened
sncRNA-ASOs are not active. Statistical B scores are constructed
based on the observation that hits behave as outliers compared to
the majority of non-effective sncRNAs-ASOs. The normalized B
scores follow a standardized Gaussian distribution, so that outliers,
our potential hits, can be defined as values below 2. A positional
effect was detected, with B score values in close columns or rows
clustering together (Figure S1). As indicated in the B score method,
we applied an iterative median polished that robustly avoids posi-
tion-related systematic errors.12
We consistently detected a decrease in cell viability in wells trans-
fected with the positive control sncRNA-ASO (Figure 2). A signif-
icant enrichment of hits was detected among the sncRNAs
expressed in our model system (Figure S2), which agrees with a
specific effect of the ASOs on sncRNAs present in differentiated
neuronal cells, thus favoring the detection of true detrimental
effects. Among the sncRNAs (988 miRNAs and 9 sncRNAs)
with mean normalized counts >1, according to sequencing analysis
(Table S2), a total of 76 sncRNA-ASOs targeting miRNAs
(miRNA-ASOs) significantly decreased viability in differentiated
SH-SY5Y (B score <2), in at least two biological replicates
(Table 1).
The second statistical approach is based on a linear mixed effects
model (LMM) that accounts for the three biological replicates as
another source of variability in the experimental design. Similar to
the B score method, the LMM uses the bulk of data as self-controls
and accounts for systematic biases. The fact that the experimental
design includes biological triplicates per sample, allows us to include
sample random effects in the model so that outliers or candidate hitsMolecular Therapy: Nucleic Acids Vol. 17 September 2019 375
Figure 2. Cell Viability Determinations in the HTFS under Basal Conditions
and in Response to Oxidative Stress
Cell viability determinations in every plate are shown in mock-transfected cells,
cells transfected with a negative control sncRNA-ASO (C), and cells trans-
fected with the positive control sncRNA-ASO (C+), under basal conditions and
following treatment with 3 mM MPP+. Each dot represents the percentage of
cell viability determinations in a well, with 100% considered to be the mock-
transfected cells under basal conditions. All values are represented relative to a
mock-transfected well under basal conditions. Differences between conditions
were determined by using linear mixed-effects models, where experimental
conditions to be compared are included in the model as fixed affects, and plates
are included as random effects to account for between-plate variability.
A Bonferroni correction was applied to account for multiple comparisons
(number of comparisons = 9). Significant differences are found between MPP+
treatment and basal conditions, in each experimental condition (Mock, C, and
C+; *p < 0.001), and in C+ versus mock and C under basal conditions and
after exposure to MPP+ (+p < 0.001).
Molecular Therapy: Nucleic Acidsare summarized in a single value. This model provided a total of 87
sncRNA-ASOs that decreased cell viability, of which 47 (54%) were
coincidental with the B score-based approach (Table 1). These data
suggest that the 47 sncRNAs targeted by the correspondent ASOs
participate in the maintenance of cell viability. According to the
miRNA enrichment analysis and annotation (miEAA) tool,24 the
pathways targeted by the group of miRNAs whose ASOs decrease
cell viability include nervous system development, apoptosis, and
DNA damage response and pathways associated with diverse neurode-
generative conditions, including Parkinson’s and Huntington’s
diseases (Table S3).
An independent HTFS was performed to evaluate the effect of
sncRNA-ASOs in cell viability after a stressful stimulus (Figure 1).
Differentiated SH-SY5Y cells were transfected with the sncRNA-
ASOs, and 24 h later, they were subjected to 1-methyl-4-phenylpyr-
idinium (MPP+) stress for an additional 24 h, after which cell
viability was determined. MPP+ impairs oxidative phosphorylation
in mitochondria by inhibiting complex I, leading to depletion of
ATP and cell death, and has been used largely to understand
dopaminergic neuronal death in Parkinson’s disease (PD).21 We
used a concentration of MPP+ (3 mM) that produced a significant
but moderate decrease (35%) in cell viability. MPP+ (3 mM) pro-376 Molecular Therapy: Nucleic Acids Vol. 17 September 2019duced a stronger decrease in cell viability by the sncRNA-ASO
used a positive control (70%), compared with basal, untreated con-
ditions (60%) (Figure 2), and permitted the identification of other
sncRNA-ASOs that worsen the response or protect it from MPP+
stress (Figure 1).
A total of 60 miRNA-ASOs impaired the effect of MPP+ in
cell viability according to both statistical methods (Table 2), of
which 22 (36.6%) were common to those that decrease cell
viability under basal conditions (Table 1). A miEAA analysis
with the group of miRNAs whose ASOs worsened the response
to MPP+ stress pointed to response to reactive oxygen species
(ROS) and apoptosis pathways (Table S4). In addition, 40
miRNA-ASOs protected from the detrimental effect of MPP+ on
cell viability (Table 2).
In summary, the HTFS identified 85 miRNA-ASOs with a detri-
mental effect in basal conditions and/or in response to MPP+, and
40 miRNA-ASOs that protect from MPP+ stress, which may reflect
the protective and detrimental roles of the targeted miRNAs,
respectively.A Subset of Detrimental miRNA-ASOs Increases Free Radical
Biogenesis and Impairs Mitochondrial Function
Generation of ROS plays a critical role in damaging cellular com-
ponents and initiating cell death. Therefore, we evaluated whether
the effect of specific miRNA-ASOs in cell viability is linked to
changes in ROS levels. We used CellROX Deep Red Reagent
(Molecular Probes) to quantify ROS levels that were expressed
with respect to the total number of cells, measured with
CyQUANT Direct Cell Proliferation Assay (Invitrogen). This
strategy permitted the detection of increased ROS levels in cells
transfected with the miRNA-ASO used as a positive control, and
a general increase in ROS levels in cells treated with 3 mM
MPP+ (Figure S3).
We chose a subset of miRNA-ASOs with a negative effect on cell
viability under basal conditions and/or in response to MPP+, a
group of miRNA-ASOs that protect against MPP+, and a subset
of miRNA-ASOs with no effect on cell viability. The subsets of
detrimental and protective miRNA-ASOs are based on the altered
expression of the targeted miRNAs in neurodegenerative condi-
tions (Table S5). We particularly focused on miRNAs perturbed
in PD paradigms, since differentiated SH-SY5Y cells are widely
used to understand neuronal death mechanisms in this disease.21
After transfection of the chosen miRNA-ASOs we evaluated
ROS levels, both under basal conditions and in response to
MPP+, as an alternative readout of cell dysfunction (Figure 3).
We calculated Pearson’s correlation coefficient to evaluate the
degree of association between the cell viability (B score) and OS
(ROS levels) measures. The statistically significant negative corre-
lation coefficient (Figure S4) suggests that both measures are
inversely associated.
Table 1. sncRNA-ASOs Decreasing Cell Viability
sncRNA ID Replicate 1 Replicate 2 Replicate 3 Average
hsa-miR-1236-3pa 15.43 3.66 5.84 8.31
hsa-miR-4758-3pa 8.84 5.99 9.63 8.15
hsa-miR-1913a 9.25 8.26 6.50 8.00
hsa-miR-5006-3pa 12.47 5.29 5.83 7.86
hsa-miR-3677-5pa 6.53 5.42 8.23 6.73
hsa-miR-204-5pa 4.99 2.48 12.39 6.62
hsa-miR-4640-3pa 4.56 6.80 8.14 6.50
hsa-miR-496a 3.48 10.49 4.55 6.18
hsa-miR-5579-3pa 6.94 7.57 3.89 6.14
hsa-miR-6817-3pa 5.11 8.36 4.89 6.12
hsa-miR-3171a 7.03 6.81 3.88 5.91
hsa-miR-6840-5pa 9.52 4.47 2.48 5.49
hsa-miR-6511a-3pa 3.70 3.80 8.34 5.28
hsa-miR-2355-5pa 1.80 7.51 6.33 5.21
hsa-miR-1224-3pa 2.68 4.31 8.14 5.04
hsa-miR-24-1-5pa 0.21 7.64 6.88 4.91
hsa-miR-133a-3pa 0.47 4.26 9.79 4.84
hsa-miR-346a 5.00 4.97 4.55 4.84
hsa-miR-3940-3pa 7.26 2.62 4.64 4.84
hsa-miR-454-5pa 1.55 4.50 8.32 4.79
hsa-miR-7976a 6.17 3.79 4.34 4.77
hsa-miR-574-3pa 2.62 8.13 3.47 4.74
hsa-miR-361-3pa 6.68 2.09 4.39
hsa-miR-5587-3p 4.67 4.73 3.36 4.25
hsa-miR-7-1-3p 4.81 3.13 3.97
hsa-miR-3200-3pa 3.05 2.10 6.76 3.97
hsa-miR-374b-5pa 3.00 1.92 6.93 3.95
hsa-miR-6511b-3p 3.38 1.08 7.11 3.86
hsa-miR-4484a 2.52 4.60 4.15 3.76
hsa-miR-532-3pa 4.42 3.76 2.60 3.59
hsa-miR-3176 3.30 2.62 4.85 3.59
hsa-miR-6770-5p 2.66 3.98 4.08 3.57
hsa-miR-500a-3pa 4.79 2.52 3.30 3.54
hsa-miR-6800-3pa 2.09 4.44 4.06 3.53
hsa-miR-1301-3p 4.18 2.91 3.31 3.47
hsa-miR-2114-5p 2.68 8.04 0.37 3.45
hsa-miR-4647 2.13 3.55 4.60 3.43
hsa-miR-4793-3p 1.59 4.78 3.84 3.40
hsa-miR-324-3pa 1.33 4.21 4.11 3.22
hsa-miR-767-3pa 4.18 3.75 1.50 3.14
hsa-miR-210-5p 0.93 2.28 6.08 3.10
hsa-miR-1914-5pa 3.14 5.55 0.59 3.09
hsa-miR-6738-3pa 2.40 3.90 2.93 3.08
hsa-miR-551b-3pa 1.95 1.64 5.46 3.02
(Continued)
Table 1. Continued
sncRNA ID Replicate 1 Replicate 2 Replicate 3 Average
hsa-miR-18a-5pa 2.70 3.34 2.97 3.00
hsa-miR-152-5p 3.01 3.25 2.70 2.99
hsa-miR-766-3pa 2.37 0.80 5.65 2.94
hsa-miR-5699-5p 5.14 1.55 2.12 2.94
hsa-miR-767-5p 2.19 4.43 2.16 2.93
hsa-miR-7974a 2.35 4.66 1.67 2.89
hsa-miR-642a-5p 1.15 4.95 2.58 2.89
hsa-miR-362-5p 2.97 3.39 2.27 2.88
hsa-miR-3116 3.25 3.10 2.25 2.87
hsa-miR-885-5pa 2.43 4.03 2.05 2.84
hsa-miR-2116-3pa 4.35 0.76 3.39 2.83
hsa-miR-636 2.76 1.39 3.96 2.70
hsa-miR-330-3p 2.97 3.20 1.90 2.69
hsa-miR-6803-3p 1.00 2.87 4.02 2.63
hsa-miR-106b-3p 2.02 0.75 5.09 2.62
hsa-miR-543a 2.08 3.87 1.90 2.62
hsa-miR-654-3pa 0.64 2.40 4.79 2.61
hsa-miR-151a-5p 1.96 2.18 3.45 2.53
hsa-miR-4685-3pa 0.08 3.24 4.19 2.50
hsa-miR-1298-5p 1.66 2.84 2.68 2.39
hsa-miR-1234-3pa 3.30 2.10 1.75 2.38
hsa-miR-758-5p 2.70 2.76 1.68 2.38
hsa-miR-4638-3p 1.39 2.76 2.92 2.35
hsa-miR-2355-3p 2.18 0.90 3.94 2.34
hsa-miR-939-3pa 3.70 2.86 0.45 2.34
hsa-miR-1305 1.72 2.12 3.02 2.29
hsa-miR-616-5pa 2.53 2.84 1.45 2.27
hsa-miR-590-3p 0.10 3.63 3.05 2.26
hsa-miR-3130-5pa 2.49 0.02 4.17 2.22
hsa-miR-551a 2.56 3.79 0.11 2.15
hsa-miR-128-3p 3.24 1.99 1.19 2.14
hsa-miR-3944-3p 2.39 0.45 3.27 2.03
Hits show amedian polished B score <2, consistent in at least two biological replicates.
Only ASOs targeting sncRNAs with mean normalized counts >1 in differentiated
SHSY5Y cells are shown.
aHits validated with a LMM.
www.moleculartherapy.orgmiRNA-ASOs impairing cell viability induced a significant increase
in ROS levels under basal conditions and in response to MPP+
(Exp 1; Figure 3C). The miRNAs-ASOs impairing cell viability, in
both basal conditions and response to OS, strongly contributed to
increased ROS levels (Exp 2a versus Exp 2b, upper panel; Figure 3C).
miRNA-ASOs with no effect on cell viability induced a slight increase
in ROS levels compared with mock-transfected cells, suggesting that
LNA-ASOs may produce minor OS (Exp 4; Figure 3C). Compared
with this group, protective miRNA-ASOs tended to decrease ROS
levels (Exp 3; Figure 3C) in agreement with their protective outcomeMolecular Therapy: Nucleic Acids Vol. 17 September 2019 377
Table 2. sncRNA-ASOs That Modify the Cell Response to Oxidative Stress
sncRNA-ASO Replicate 1 Replicate 2 Replicate 3 Average sncRNA-ASO Replicate 1 Replicate 2 Replicate 3 Average
hsa-miR-636a 11.08 8.06 7.50 8.88 hsa-miR-363-5p 1.93 3.91 0.97 2.27
hsa-miR-6840-5pa -7.63 -8.46 -5.76 -7.28 hsa-miR-146b-3pa 2.60 2.69 1.52 2.27
hsa-miR-204-5pa -6.19 -7.23 -7.66 -7.03 hsa-miR-410-3pa 2.42 2.92 1.46 2.27
hsa-miR-1236-3pa -8.41 -7.02 -4.92 -6.78 hsa-miR-330-3p 2.34 2.43 2.02 2.26
hsa-miR-532-3pa -8.45 -5.70 -5.86 -6.67 hsa-miR-1253 3.69 2.01 1.07 2.26
hsa-miR-5006-3pa -4.23 -8.42 -5.45 -6.03 hsa-miR-6806-3p 2.13 3.79 0.84 2.25
hsa-miR-6803-3p 9.90 3.96 3.26 5.71 hsa-miR-6857-3p 2.14 3.98 0.50 2.21
hsa-miR-6817-3pa -3.66 -4.75 -7.49 -5.30 hsa-miR-574-3pa -2.55 -1.41 -2.66 -2.21
hsa-miR-362-5pa 4.45 4.87 6.14 5.16 hsa-miR-6511a-3pa -2.67 -2.14 -1.80 -2.20
hsa-miR-1271-5pa 2.38 4.76 8.01 5.05 hsa-miR-129-2-3pa 1.54 2.32 2.74 2.20
hsa-miR-2355-5pa -3.03 -6.88 -4.29 -4.74 hsa-miR-3176a 2.60 2.87 1.10 2.19
hsa-miR-4522 4.50 6.35 3.15 4.67 hsa-miR-99b-5p 2.89 1.49 2.15 2.18
hsa-miR-1913a -5.73 -2.95 -5.31 -4.66 hsa-miR-6797-3pa 2.62 2.89 0.81 2.11
hsa-miR-454-5pa -7.71 -3.05 -3.00 -4.59 hsa-miR-342-3p 2.68 0.59 2.95 2.07
hsa-miR-6511b-3pa 5.59 3.85 4.26 4.57 hsa-miR-548s 2.83 1.01 2.33 2.06
hsa-miR-4479 3.90 4.18 5.39 4.49 hsa-miR-4767a 2.08 2.71 1.36 2.05
hsa-miR-7977a 6.04 4.55 2.62 4.40 hsa-miR-615-3p 2.25 3.29 0.55 2.03
hsa-miR-133a-3pa -3.20 -5.02 -4.84 -4.35 hsa-miR-143-5p 3.48 2.65 0.08 2.01
hsa-miR-654-5p 6.43 3.00 3.23 4.22 hsa-miR-182-5p 2.73 2.37 0.61 1.50
hsa-miR-767-5pa 2.02 4.82 5.80 4.21 hsa-miR-548b-5pa 0.83 3.30 3.57 2.01
hsa-miR-24-2-5pa 4.44 2.25 5.86 4.18 hsa-miR-7854-3pa 0.41 2.89 2.89 2.06
hsa-miR-6750-3p 5.93 4.33 1.98 4.08 hsa-miR-4745-5pa 1.15 2.56 2.49 2.07
hsa-miR-615-5pa 2.41 4.51 5.31 4.07 hsa-miR-197-5pa 2.19 2.79 1.37 2.12
hsa-miR-642a-5pa 1.02 4.78 6.32 4.04 hsa-miR-6129a 2.01 3.18 1.19 2.12
hsa-miR-766-3pa -4.95 -3.95 -2.80 -3.90 hsa-miR-548l 4.41 0.52 2.77 2.22
hsa-miR-4685-3pa -2.77 -4.40 -4.32 -3.83 hsa-miR-548b-3p 2.54 2.15 2.11 2.27
hsa-miR-346a -4.33 -3.04 -3.69 hsa-miR-3126-5pa 0.26 4.11 2.65 2.34
hsa-miR-6798-3pa 3.26 3.42 4.11 3.59 hsa-miR-101-3pa 0.57 2.34 4.15 2.35
hsa-miR-4642a 7.34 3.31 0.06 3.57 hsa-miR-656-3p 0.95 2.94 3.26 2.38
hsa-miR-3619-5p 4.64 3.02 2.95 3.54 hsa-miR-4443a 1.04 2.03 4.10 2.39
hsa-miR-605-5pa 3.41 4.68 2.50 3.53 hsa-miR-5695a 3.73 1.95 1.82 2.50
hsa-miR-1226-5p 3.29 1.28 5.77 3.44 hsa-miR-505-5pa 5.36 0.81 3.05 2.53
hsa-miR-4758-3pa -3.91 -1.23 -5.18 -3.44 hsa-miR-9-3p 3.59 2.62 1.54 2.58
hsa-miR-1914-5p 3.48 2.52 4.32 3.44 hsa-miR-548ka 3.22 2.72 1.97 2.64
hsa-miR-5587-3p -2.10 -3.78 -4.38 -3.42 hsa-miR-651-5pa 3.25 2.50 2.21 2.65
hsa-miR-152-5p 6.01 1.46 2.69 3.39 hsa-miR-876-5pa 0.00 5.17 2.97 2.71
hsa-miR-4800-3p 5.11 2.29 2.63 3.34 hsa-miR-425-3p 1.94 4.33 1.87 2.71
hsa-miR-339-5pa 3.82 2.36 3.78 3.32 hsa-miR-574-5pa 2.79 2.94 2.71 2.81
hsa-miR-767-3pa -2.00 -5.01 -2.93 -3.31 hsa-miR-548e-3pa 5.30 2.28 0.94 2.84
hsa-miR-3938 3.73 3.39 2.79 3.30 hsa-miR-200c-3pa 1.36 3.20 3.98 2.85
hsa-miR-99a-5pa 4.30 2.27 3.28 hsa-miR-629-5pa 2.70 1.49 4.48 2.89
hsa-miR-455-3pa 3.94 3.50 2.38 3.27 hsa-miR-766-5p 4.21 3.50 1.26 2.99
hsa-miR-26a-1-3pa 4.39 3.52 1.74 3.22 hsa-miR-1303a 0.67 4.57 3.76 3.00
(Continued on next page)
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Table 2. Continued
sncRNA-ASO Replicate 1 Replicate 2 Replicate 3 Average sncRNA-ASO Replicate 1 Replicate 2 Replicate 3 Average
hsa-miR-6738-3pa -3.19 -3.97 -2.47 -3.21 hsa-miR-3163a 2.23 6.21 0.74 3.06
hsa-miR-874-5pa 4.32 1.80 3.34 3.16 hsa-miR-105-3p 1.44 3.84 3.91 3.07
hsa-miR-331-3pa 2.94 3.32 3.13 hsa-miR-10b-3pa 5.86 0.92 2.67 3.15
hsa-miR-2277-3p 2.64 2.68 4.00 3.11 hsa-miR-215-5pa 3.49 2.96 3.23
hsa-miR-152-3pa 2.32 3.73 3.03 hsa-miR-1185-5pa 3.30 1.95 4.92 3.39
hsa-miR-361-3pa -1.00 -4.74 -3.33 -3.03 hsa-miR-3141a 0.14 2.70 7.48 3.44
hsa-miR-329-3pa 3.24 2.43 3.40 3.02 hsa-miR-1268aa 0.94 5.76 3.64 3.45
hsa-miR-4516 3.59 3.68 1.68 2.98 hsa-miR-193b-5pa 1.48 3.86 5.04 3.46
hsa-miR-3130-5p 5.37 3.71 0.15 2.98 hsa-miR-4705a 3.57 4.43 2.41 3.47
hsa-miR-370-5p 2.46 3.19 3.21 2.96 hsa-miR-3609a 2.18 2.82 6.28 3.76
hsa-miR-6800-3pa -4.01 -2.06 -2.79 -2.95 hsa-miR-320a 4.71 2.91 3.81
hsa-miR-105-5pa 4.71 3.74 0.28 2.91 hsa-miR-221-5pa 6.00 1.98 3.52 3.83
hsa-miR-106b-3p 1.71 3.65 3.30 2.89 hsa-miR-219a-1-3pa 6.93 3.64 1.00 3.86
hsa-miR-6726-3pa 4.97 2.07 1.49 2.84 hsa-miR-29b-1-5pa 2.71 4.73 4.21 3.88
hsa-miR-4746-5pa 2.24 3.82 2.35 2.80 hsa-miR-1277-3pa 5.78 3.07 3.06 3.97
hsa-miR-151a-5p 2.58 2.88 2.86 2.77 hsa-miR-134-5pa 3.63 4.96 3.34 3.98
hsa-miR-15a-3p 3.22 3.81 1.16 2.73 hsa-miR-1269pa 6.33 3.70 1.99 4.01
hsa-miR-3187-3pa 3.30 1.91 2.84 2.69 hsa-miR-627-5p 1.43 7.54 3.40 4.12
hsa-miR-129-1-3pa 0.67 3.15 5.52 2.67 hsa-miR-590-5p 5.24 3.92 3.44 4.20
hsa-miR-496a -2.42 -1.26 -4.29 -2.65 hsa-miR-99a-3pa 6.49 2.23 4.41 4.38
hsa-miR-23a-3pa 4.22 2.13 1.55 2.63 hsa-miR-147pa 5.29 4.50 4.11 4.63
hsa-miR-1296-3pa 0.81 2.87 4.11 2.60 hsa-miR-585-3pa 3.89 5.75 4.51 4.72
hsa-miR-1538 3.61 2.28 1.79 2.56 hsa-miR-186-3pa 5.11 4.76 4.29 4.72
hsa-miR-148a-5pa 1.35 3.27 2.78 2.47 hsa-miR-664a-5pa 7.02 2.83 4.92 4.92
hsa-miR-550a-3pa 4.37 0.79 2.14 2.43 hsa-miR-6847-5pa 7.62 3.90 3.65 5.06
hsa-let-7d-3pa 1.21 3.76 2.12 2.36 hsa-miR-1268ba 12.43 9.03 7.61 9.69
Hits show amedian polished B score <2; worsening cell viability in response to MPP+; or B score >2, which protects against the detrimental effect of MPP+, consistent between at least
two biological replicates. Only ASOs targeting sncRNAs with mean normalized counts >1 in differentiated SHSY5Y cells treated with 3 mM MPP+ for 24 h, are shown. ASOs high-
lighted in bold are common to those found in basal conditions (Table 1).
aHits validated with a LMM.
www.moleculartherapy.orgin viability determinations. Overall, these data indicate that ROS
levels confirm the previously selected hits, especially those producing
a detrimental effect on cell viability.
To test whether the detrimental effect of miRNA-ASOs was linked
to mitochondrial dysfunction, we measured the mitochondrial
membrane potential by using Mitotracker fluorescent dye
(Molecular Probes). We selected ASOs targeting miR-204-5p,
miR-532-3p, and miR-324-3p, which are reliably expressed in
the human brain, perturbed in several neurodegenerative and
neurological disorders,20,25–31 and involved in neuronal differenti-
ation.32–34
Confirming the effect of three miRNA-ASOs in decreasing cell
viability (Tables 1 and 2) and inducing ROS, miR-204-5p-,
miR-324-3p-, and miR-532-3p-ASO significantly impaired mito-
chondrial membrane potential (Figure 4). These results suggest thatthe activity of these miRNAs is important for neuronal survival and
response to MPP+ stress.
miRNA Expression Dynamics in Response to MPP+ May
Contribute to Cell Dysfunction
Inhibition of sncRNAs activity may reflect, at least to some extent, the
consequences of the downregulation of the targeted sncRNAs that
occurs in response to specific stimuli. We analyzed the sncRNA
expression profiles in response to MPP+ to understand if sncRNA
dynamics contribute to cell viability outcome. SH-SY5Y cells were
differentiated, and sncRNA expression profiles were determined by
deep sequencing 24 h after exposure to MPP+ (3 mM). A total of
128 miRNAs were significantly deregulated after exposure to MPP+
(Table 3).
Among the miRNAs whose ASOs worsened cell viability in basal con-
ditions and/or response to MPP+ (according to both statistical tests),Molecular Therapy: Nucleic Acids Vol. 17 September 2019 379
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Figure 3. Validation of HTFS Hits Based on the
Evaluation of ROS Levels
Plots of relative ROS levels in cells transfected with
sncRNA-ASOs in basal conditions (A) and after exposure
to 3 mM MPP+ (B). ROS levels in each biological replicate
are represented by a dot and expressed relative to a
control mock-transfected well. In the plots, numbers, and
colors correspond to the diverse transfected sncRNA-
ASOs: blue, sncRNA-ASOs that impair cell viability in basal
conditions (asterisks label miRNA-ASOs that impair cell
viability both under basal conditions and in response to
MPP+); green, sncRNA-ASOs that worsen cell viability in
response to MPP+; orange, sncRNA-ASOs that protect
against MPP+; black, ncRNA-ASOs with no effect on cell
viability, including a scrambled sequence used as a
negative control (C); red, an ASO with a known toxic
effect used as a positive control (C+). (C) Plot showing the
fold change (FC) of ROS levels in cells transfected with
miRNA-ASOs versus mock-transfected cells, under basal
conditions (upper panel) or in response to MPP+ (lower
panel). Exp1: FC considering the miRNA-ASOs in blue;
Exp2a, FC considering miRNA-ASOs in green and those
in blue marked with an asterisk; Exp2b, FC considering
miRNA-ASOs in green; Exp3, FC considering miRNA-
ASOs in orange; and Exp4, FC considering miRNA-ASOs
in black.
Molecular Therapy: Nucleic Acidshsa-miR-7974, miR-3619-5p, miR-455-3p, miR-3176, miR-3187-3p,
miR-636, and miR-454-5p were downregulated after exposure to
MPP+ (Table 3), which suggests that their deregulation pattern
may contribute to impairment of cell viability. For four downregu-
lated miRNAs—miR-4745-5p, miR-574-5p, miR-1303, and miR-
6847-5p—the correspondent ASOs protected from MPP+ stress.
Among the MPP+-downregulated miRNAs, the increased number
of detrimental ASOs versus protective ones is in contrast with the
few hits found among the MPP+-upregulated miRNAs (only one
protective and one detrimental miRNA-ASO).
We used the miEAA tool to identify the pathways targeted by
MPP+-deregulated miRNAs (Tables S6 and S7). The analysis
showed that MPP+-downregulated miRNAs were significantly
depleted in signaling pathways related to stress, including apoptosis,380 Molecular Therapy: Nucleic Acids Vol. 17 September 2019oxidative stress response, p53, andDNA damage
response. In addition, MPP+-upregulated
miRNAs were enriched in analogous pathways.
Furthermore, MPP+-deregulated miRNAs
were significantly perturbed in Alzheimer’s-,
Parkinson’s-, and Huntington’s-disease-related
pathways. Overall, these data suggest that the
miRNA expression dynamics in response to
MPP+ contributes to detrimental processes.
DISCUSSION
The evidence shows that perturbed activity of spe-
cific sncRNAs influence neuronal function under
both normal and pathological conditions. In thepresent study we developed an HTFS to generally identify sncRNAs
involved in neuronal cell viability, both under basal conditions and in
response to OS, a major player in neurodegenerative processes.
Here, we used LNA-modified AOSs that bind to target sequences and
decrease the availability and activity of each particular sncRNA.
Although LNA modifications in ASOs increase stability and speci-
ficity for the target sequence,35 binding to unintended targets could
account for nonspecific effects in cell viability. However, the signifi-
cant enrichment of hits among SH-SY5Y-expressed sncRNAs favors
the idea that LNA-ASOs induce a detrimental effect by specifically
targeting sncRNAs expressed in our model system.
To identify reliable sncRNA-ASOs affecting cell viability, we used the
B score method, which is designed to detect hits in HTFS.19 We
Figure 4. Mitochondrial Activity after Transfection with Specific
miRNA-ASOs
Mock, cells treated with Lipofectamine; negative control (C), cells transfected with
an ASO that does not produce any effect in cell viability; positive control (C+), cells
transfected with a control sncRNA-ASO inducing cell death; positive control
(CCCP), cells treated with CCCP were used as a positive control for mitochondrial
functional loss. The boxplot shows absorbance determinations after incubation with
MitoTracker Deep Red reagent. *p < 0.001, by the Kruskal-Wallis test, followed by
the Mann-Whitney U test with Bonferroni’s correction as a post hoc test (n = 5).
www.moleculartherapy.orgapplied an iterative median polish that robustly avoids row- and
column-position-related systematic errors, which we detected in the
different HTFSs. Z scores are also based on the raw sample values;
however, as Brideau and colleagues19 discussed, these scores suffer
from the fact that they do not take into account positional effects,
and their performance is compromised by outliers, which are the
key hits. However, when no positional effects and changes occur in
a plate, Z scores are slightly more efficient. That is why the combina-
tion of different methods may help to choose the best top hits. Under
this premise, we proposed another statistical approach that is based
on Z scores, but improved in a way similar to the B score. The
approach is based on a LMM, where the positional effects are taken
into account, and, in addition, it considers the three independent rep-
licates as a source of variability in the experimental design. This
method detected from 55% to 70% of the B score hits, and additional
functional validations were performed for a subset of sncRNA-ASOs
commonly identified in both strategies.
Only sncRNA-ASOs targeting canonical miRNAs produced signifi-
cant effects in cell viability in agreement with both statistical methods.
According to the miEAA (Tables S3 and S4), the pathways targeted
by the group of miRNAs whose ASOs decrease cell viability favor
the idea that the detrimental effects of the miRNA-ASOs are not
nonspecific but are caused by the selective blockage of miRNAs
that participate in neuronal survival.
miRNA-ASOs that impair cell viability in basal conditions and/or in
response to MPP+ may prevent the activity of miRNAs involved in
neuronal maintenance or in neuronal protection in front of OS.
Conversely, miRNA-ASOs protecting from MPP+ stress may target
miRNAs contributing to MPP+-mediated cell death. Our resultshave validated the toxic effect of miRNA-ASOs tested in other HTFSs,
including miR-204; miR-210 inhibitors in HeLa cells;36 and miR-
133a-3p, miR-361-3p, and miR-346 inhibitors in lung cancer cells.37
In addition, in line with the detrimental effect of the miR-7-1-3p-ASO
observed in the present study, miR-7-1 activity is involved in motor
neuron protection.38 miR-134-5p expression induces neuronal death
in the brain,39 which agrees with the protective effect of miR-134-
5p-ASO in front of the stressful conditions observed here. Further-
more, reduction of miR-23a following traumatic brain injury induces
neuronal death,40 which matches with the worsened effect of the
correspondent ASO observed in the present study.
Although our results validate many of the miRNAs reported to have a
role in cell viability, there are some exceptions. The present study did
not reveal the neuroprotective activity of miR-7-5p andmiR-153.41 In
addition, we did not reproduce the neuroprotective effect of miR-181
inhibition42 or the detrimental effect of miR-29b inhibition43 in front
of cerebral ischemia. Whether the lack of confirmation is because the
activity of these miRNAs is context dependent or involves alternative
experimental conditions remains to be determined. Validation of the
present results in diverse cell types, including primary neurons, is
needed to understand how general and consistent the effects of the
miRNA-ASOs reported herein are. Furthermore, evaluation of the
effect of miRNA-ASOs in the brain in model organisms will answer
whether validation in simpler neuronal cell cultures can be extended
to a complex structure with heterogeneous neuronal and non-
neuronal (glial) cells.
The temporal and spatial miRNA dynamics regulate gene expression
programs in normal conditions and in response to stressful stimuli.
The effect of miRNA-ASOs mimic the consequences of miRNA
downregulation, and our data suggest that the overall miRNA expres-
sion patterns in response to MPP+ contribute to MPP+-mediated
damage. Analogous assumptions considering the miRNA expression
patterns in human brains in neurodegenerative conditions are diffi-
cult to determine. Neurodegenerative diseases involve continuous
and long-lasting molecular changes that shape disease evolution.
For instance, according to our data, miR-204-5p and miR-532-3p
are protective miRNAs (their inhibition impairs cell viability). In
the substantia nigra of PD patients, miR-204-5p is upregulated, and
miR-532-5p is downregulated;27 however, both miRNAs are downre-
gulated in the amygdala of PD patients.20,27 It is difficult to anticipate
the significance of these changes, since neuropathological alterations
strongly differ in these two brain areas. Furthermore, the expression
pattern of miR-128-3p, another miRNA that we have identified as
neuroprotective, differs in the amygdala of PD patients, showing
downregulation at pre-clinical stages and upregulation at clinical
stages.20 miRNA expression dynamics may reflect complex reactive
responses with functional consequences, either protecting from stress
or contributing to dysfunction, depending on the brain regions and
disease evolutionary stages. Experimentally induced alterations in
the activity of miRNAs in vivo should highlight the relevance that
changes in the expression levels of particular miRNA (or groups of
miRNAs) undergo in a pathogenic process.Molecular Therapy: Nucleic Acids Vol. 17 September 2019 381
Table 3. miRNAs Significantly Deregulated, 24 h after Treatment with 3 mM MPP
miRNA
Mean
Normalized
Counts
Log2 Fold
Change
24 h MPP+
versus C padj
Average
B Score
Basal
Assay
Average
B Score
MPP+
Assay miRNA
Mean
Normalized
Counts
Log2 Fold
Change 24 h
MPP+
versus C padj
Average
B Score
Basal
Assay
Average
B Score
MPP+
Assay
hsa-let-7a-5p 212,828.53 0.46 0.01 3.00 0.77 hsa-miR-335-5p 33.84 0.73 0.02 1.29 0.30
hsa-let-7c-5p 9,910.12 0.47 0.03 0.65 1.51 hsa-miR-34a-3p 65.64 1.09 0.00 1.18 1.46
hsa-let-7f-1-3p 37.86 1.00 0.00 0.48 0.09 hsa-miR-34a-5p 1,366.74 0.98 0.00 1.50 0.58
hsa-let-7i-5p 23,119.45 0.34 0.00 1.18 0.45 hsa-miR-34b-3p 17.96 1.54 0.00 0.27 0.06
hsa-miR-10a-5p 628.77 0.53 0.04 3.57 0.95 hsa-miR-34b-5p 62.77 1.88 0.00 1.16 1.58
hsa-miR-1180-3p 1,366.77 0.60 0.00 1.57 1.06 hsa-miR-34c-5p 1,062.35 1.91 0.00 0.60 0.81
hsa-miR-1224-5p 83.98 0.60 0.01 1.72 0.90 hsa-miR-3615 1,227.71 0.40 0.02 0.02 0.14
hsa-miR-1247-5p 78.77 0.60 0.00 1.73 1.92 hsa-miR-3619-5p 15.30 1.73 0.00 0.54 3.54
hsa-miR-125b-1-3p 1,030.31 0.47 0.01 2.16 0.35 hsa-miR-3679-5p 20.00 0.97 0.01 0.44 0.70
hsa-miR-126-3p 1,021.38 0.21 0.03 0.28 0.92 hsa-miR-378a-3p 3,805.50 0.41 0.00 0.30 1.17
hsa-miR-126-5p 5,597.90 0.39 0.00 0.94 0.01 hsa-miR-378i 14.00 0.92 0.01 1.29 1.45
hsa-miR-1260a 3,628.71 0.81 0.00 3.77 0.74 hsa-miR-381-3p 1,565.58 0.36 0.00 0.45 1.67
hsa-miR-1260b 3,920.23 0.79 0.00 1.47 0.33 hsa-miR-3909 142.17 0.62 0.00 2.21 0.58
hsa-miR-1272 13.23 2.00 0.00 0.95 0.97 hsa-miR-3929 44.66 1.10 0.00 0.80 1.60
hsa-miR-1276 240.10 0.56 0.00 1.67 1.00 hsa-miR-3939 17.64 0.78 0.02 0.08 1.33
hsa-miR-1298-3p 14.61 1.45 0.00 1.30 0.26 hsa-miR-409-3p 1,080.93 0.36 0.01 1.63 1.60
hsa-miR-1298-5p 289.63 1.68 0.00 2.39 1.76 hsa-miR-424-5p 312.73 0.64 0.00 0.13 0.04
hsa-miR-1303 152.76 1.30 0.00 0.89 3.00 hsa-miR-425-3p 924.49 0.33 0.00 0.15 2.71
hsa-miR-130b-5p 2,949.55 0.41 0.00 0.75 0.19 hsa-miR-4284 28.38 2.82 0.00 0.41 0.42
hsa-miR-132-3p 6,025.80 0.67 0.02 1.22 0.25 hsa-miR-4301 53.24 1.15 0.00 1.34 0.50
hsa-miR-135a-3p 73.40 0.88 0.00 0.77 0.25 hsa-miR-4455 455.18 0.90 0.00 2.71 1.17
hsa-miR-135a-5p 143.13 0.51 0.03 0.15 1.36 hsa-miR-448 79.61 1.00 0.00 0.24 2.77
hsa-miR-138-1-3p 547.79 0.86 0.00 2.14 0.95 hsa-miR-449a 47.36 0.57 0.03 0.42 0.47
hsa-miR-140-3p 7,556.14 0.25 0.02 0.13 1.61 hsa-miR-4516 15.07 0.96 0.01 0.41 2.98
hsa-miR-146a-5p 77.95 0.51 0.04 1.97 0.42 hsa-miR-454-5p 459.79 0.42 0.01 4.79 4.59
hsa-miR-149-5p 3,328.89 0.49 0.00 1.38 0.60 hsa-miR-455-3p 65.94 0.80 0.03 0.20 3.27
hsa-miR-152-5p 367.41 0.29 0.03 3.41 3.39 hsa-miR-4638-3p 24.56 0.70 0.04 2.35 1.40
hsa-miR-17-5p 13,154.08 0.22 0.01 1.15 1.85 hsa-miR-4741 79.93 0.72 0.01 0.24 0.13
hsa-miR-181a-3p 1,831.47 0.50 0.00 0.30 0.37 hsa-miR-4745-5p 60.91 0.79 0.03 0.80 2.07
hsa-miR-182-5p 46,002.45 0.39 0.04 0.03 1.50 hsa-miR-4792 680.59 1.29 0.00 0.58 1.29
hsa-miR-183-3p 148.31 0.62 0.00 0.10 1.35 hsa-miR-483-3p 69.91 1.22 0.00 0.56 2.00
hsa-miR-183-5p 5,824.28 0.38 0.01 0.46 0.42 hsa-miR-486-3p 81.75 0.82 0.03 0.34 0.38
hsa-miR-1908-5p 48.76 0.72 0.01 2.47 1.93 hsa-miR-486-5p 5,471.97 0.55 0.01 1.76 1.36
hsa-miR-192-5p 5,963.58 0.79 0.00 0.19 0.55 hsa-miR-489-3p 709.95 1.86 0.00 0.33 1.31
hsa-miR-193a-5p 62.50 0.75 0.02 1.44 1.57 hsa-miR-490-5p 37.79 0.99 0.00 0.28 0.37
hsa-miR-193b-3p 235.11 0.32 0.04 0.43 1.42 hsa-miR-497-5p 2,210.67 0.40 0.04 4.12 0.67
hsa-miR-194-5p 429.58 0.49 0.00 0.15 0.24 hsa-miR-499a-5p 25.96 1.20 0.00 0.30 1.77
hsa-miR-195-3p 154.61 0.54 0.00 1.92 1.10 hsa-miR-501-3p 5,352.55 0.38 0.04 0.56 0.45
hsa-miR-195-5p 1,398.68 0.55 0.01 1.09 0.51 hsa-miR-532-5p 12,026.27 0.23 0.05 0.08 1.33
hsa-miR-197-3p 4,746.12 0.47 0.00 1.20 1.18 hsa-miR-548h-5p 53.59 0.52 0.03 2.32 0.54
hsa-miR-200b-3p 20.49 0.64 0.03 0.36 0.71 hsa-miR-550a-3p 258.48 0.42 0.01 0.10 2.43
hsa-miR-20b-5p 584.11 0.50 0.00 0.95 1.24 hsa-miR-550a-5p 316.40 0.45 0.00 1.19 1.03
(Continued on next page)
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Table 3. Continued
miRNA
Mean
Normalized
Counts
Log2 Fold
Change
24 h MPP+
versus C padj
Average
B Score
Basal
Assay
Average
B Score
MPP+
Assay miRNA
Mean
Normalized
Counts
Log2 Fold
Change 24 h
MPP+
versus C padj
Average
B Score
Basal
Assay
Average
B Score
MPP+
Assay
hsa-miR-210-5p 73.28 0.46 0.04 3.10 0.42 hsa-miR-574-5p 752.87 0.90 0.00 1.27 2.81
hsa-miR-212-3p 1,057.58 0.77 0.02 1.72 0.09 hsa-miR-576-5p 202.17 0.51 0.00 1.29 1.47
hsa-miR-212-5p 423.95 0.75 0.01 1.03 0.47 hsa-miR-584-5p 1,617.69 0.62 0.00 0.25 1.63
hsa-miR-219a-1-3p 35.29 0.54 0.03 0.02 3.86 hsa-miR-627-5p 70.33 0.78 0.00 1.48 4.12
hsa-miR-22-3p 183,682.84 0.16 0.03 0.15 0.09 hsa-miR-636 57.03 0.82 0.00 2.70 8.88
hsa-miR-222-3p 734.01 0.32 0.02 0.24 0.67 hsa-miR-6516-5p 27.95 0.72 0.01 1.00 0.41
hsa-miR-23a-5p 126.01 0.89 0.00 0.62 0.30 hsa-miR-653-3p 60.24 1.85 0.00 1.38 2.09
hsa-miR-25-5p 984.00 0.51 0.00 0.60 0.70 hsa-miR-653-5p 60.58 1.39 0.00 2.44 0.06
hsa-miR-26b-3p 273.41 0.38 0.04 2.73 1.31 hsa-miR-671-3p 2,130.38 0.44 0.02 0.00 0.83
hsa-miR-26b-5p 23,380.92 0.41 0.00 2.77 1.16 hsa-miR-6716-3p 47.82 0.57 0.04 1.72 2.98
hsa-miR-27a-5p 477.16 0.56 0.00 2.51 0.38 hsa-miR-6847-5p 15.45 0.82 0.03 3.04 5.06
hsa-miR-27b-5p 2,323.36 0.34 0.04 0.19 0.91 hsa-miR-760 345.77 0.53 0.02 1.92 2.44
hsa-miR-301a-5p 125.21 0.49 0.04 0.31 0.52 hsa-miR-769-5p 14,172.66 0.33 0.00 1.18 0.45
hsa-miR-30a-3p 1,131.05 0.34 0.00 0.47 0.19 hsa-miR-7974 370.02 2.32 0.00 2.89 0.21
hsa-miR-30b-3p 46.79 0.63 0.04 0.05 1.84 hsa-miR-873-3p 1,154.19 0.53 0.00 0.20 0.99
hsa-miR-3158-3p 118.66 0.68 0.00 0.25 1.71 hsa-miR-887-3p 5,009.15 0.27 0.00 0.52 1.03
hsa-miR-3174 23.19 0.78 0.01 0.68 1.61 hsa-miR-887-5p 207.56 0.65 0.00 2.86 0.28
hsa-miR-3176 216.31 0.68 0.00 3.59 2.19 hsa-miR-92a-1-5p 180.98 0.81 0.00 1.61 0.55
hsa-miR-3187-3p 57.82 0.98 0.00 1.07 2.69 hsa-miR-92b-5p 173.91 0.49 0.00 0.75 1.29
hsa-miR-328-3p 528.91 0.45 0.00 1.20 0.95 hsa-miR-93-3p 1,166.74 0.33 0.02 3.47 0.92
hsa-miR-335-3p 29.44 0.84 0.00 0.77 0.82 hsa-miR-935 980.02 0.45 0.00 1.10 0.05
hsa-miR-98-5p 7,822.48 0.67 0.00 0.95 1.18
The B score under basal conditions and following MPP+ treatment is shown for each ASO targeting the corresponding deregulated miRNA. padj., adjusted p value.
www.moleculartherapy.orgIn summary, the present study provides a catalog of protective and
detrimental miRNAs with activity that affects neuronal viability,
both in resting conditions and/or in response to oxidative stress.
Our approach is a first step in defining druggable miRNAs in preclin-
ical studies aiming at validating the manipulation of miRNA activity
as a therapeutic strategy in neurological and neurodegenerative
disorders.
MATERIALS AND METHODS
Cell Cultures
SH-SY5Y cells were grown in DMEM with L-glutamine
(Biowest), supplemented with 10% inactivated fetal bovine serum
(FBSi; Gibco), 1% of penicillin-streptomycin (P/S; Gibco), and
250 ng/mL of amphotericin B (Sigma-Aldrich). SH-SY5Y
cells were differentiated for 4 days with retinoic acid (RA; Merck)
at 10 mM and for 3 days with 12-O-tetradecanoylphorbol-
13-acetate (TPA; Merck) at 80 nM. This protocol was adapted
from Presgraves et al.44 Approximately 5,000 cells were seeded
per well in 96-well plates (Thermo Fisher Scientific), using a Mul-
tidrop 348 (Thermo Fisher Scientific) or in 100,000 cells in 6-well
plates.Transfection of LNA-Modified ASOs
The library consisted of 1,954 miRNA-ASOs plus 50 custom
sncRNA-ASOs (Human miRCURY LNA microRNA Inhibitor
Library 190103; Exiqon). Transfection was performed using a Sci-
clone AHL 3000 (Caliper). Briefly, 50 mL of transfection mix was
added to differentiated cells grown in 100 mL of differentiation me-
dium. The transfection mix consisted of 43.5 mL of Opti-MEM
(Gibco), 0.5 mL of Lipofectamine 2000, and 6 mL of miRNA- or
sncRNA-ASO. The final concentration of the ASO was 70 nM.
Then, 100 mL of the transfection medium was removed 24 h later
with a Platewasher ELx405 (BioTek Instruments) and replaced with
100 mL of fresh differentiation medium, with a Multidrop 348.
Each plate was transfected with 58 unique miRNA- or sncRNA-ASO,
a negative mock-transfected control, and a positive control, consisting
of a sncRNA-ASO with known detrimental activity. The peripheral
wells were not included in the analysis and contained only medium.
The 2,004 sncRNA-ASOs were distributed in 37 plates, and transfec-
tions were performed in triplicate. An additional plate was included
in triplicate containing mock-transfected cells (treated only with
Lipofectamine 2000; Thermo Fisher Scientific); cells transfectedMolecular Therapy: Nucleic Acids Vol. 17 September 2019 383
Molecular Therapy: Nucleic Acidswith a sncRNA-ASO that does not alter cell viability, used as the nega-
tive control (miRCURY LNA Inhibitor Negative Control A; Exiqon);
and cells transfected with a sncRNA-ASO, inducing cell death, used as
a positive control (Custom miRCURY LNA Inhibitor Positive Con-
trol A; Exiqon). Taking into account all conditions and the replicates,
the HTFS included 114 plates.
Two independent HTFSs were performed in triplicate to evaluate the
effect of the miRNA- or sncRNA-ASOs in basal conditions and in
response to MPP+ stress. In the HTFS under basal conditions, cell
viability was determined 24 h after the addition of the fresh medium
(48 h after transfection). In the HTFS aiming to evaluate the response
to MPP+, the fresh medium contained MPP+ at a final concentration
of 3 mM. In this case, viability was determined 24 h after treatment
with MPP+ and 48 h after transfection.MPP+ Treatment
To evaluate the involvement of miRNA- or sncRNA-ASOs in in the
neuronal response to oxidative stress, cells were treated with MPP+.
After differentiation and 24 h following transfection in 96-well plates,
the cells were treated with a dose of MPP+ (3 mM, final concentra-
tion; Sigma-Aldrich), inducing a moderate effect on cell viability
(30%–40% decrease), which was determined 24 h later.
MPP+ (3 mM) treatment was also performed in six-well plates after
SHSY-5Yseeding (100,000cells perwell) anddifferentiation, to evaluate
sncRNA perturbations occurring as a consequence of MPP+ stress.Cell Viability Determinations
Cell viability was assessed with the WST-1 reagent45 (Roche) 48 h
after transfection. WST-1 was added to the cell medium at a ratio
of 1:10. WST-1 was dispensed using a Sciclone AHL 3000. Cell plates
were incubated withWST-1 at 37C for 2 h. Then, each plate was read
twice: at 440 nm and at 690 nm, using an Infinite M200 instrument
(Tecan). The final absorbance value was the result of subtracting
the 690 nm absorption measure from that at 440 nm and from that
of a blank plate. This blank plate was also measured at 440 and
690 nm and contained growth medium without cells and WST-1 at
a ratio of 1:10.
In the HTFS to evaluate the response to MPP+, a triplicate plate was
added to measure the effect of MPP+ in cell viability in mock-trans-
fected cells and in cells transfected with the sncRNA-ASO used as a
positive control.Hits Detection Based on B Score
The B score method19 is based on the median, which is not distorted
by outliers (the hits or ASOs affecting cell viability):
bi =
xi medðxÞ
madðxÞ :
In this equation,medðxÞ is the median of all sample values on a plate,
whereasmadðxÞ is the median absolute deviation. The numerator and384 Molecular Therapy: Nucleic Acids Vol. 17 September 2019denominator were adjusted to account for systematic biases. A row-
column-additive model was added to the plate using the two-way
median polish procedure xrcp = mp + Rrp + Ccp + ercp, where xrcp
is the raw value of a sample in row r, column c, and plate p. mp is
the plate median, Rrp is the row effect, and Ccp is the column effect.
Under this model, ercp is the plate-specific row-and-column-normal-
ized value of xrcp. Taking all that into account, the final B score was
obtained by:
b’i =
ercp
madpðeÞ:
As this positional-effect-normalized B score behaves as a standard-
ized Gaussian distribution, the hits can be defined as values below
2 (two SDs) in the screening looking at neuronal survival. In the
screening related to compounds affecting viability under OS, values
below 2 are considered to worsen viability in an OS context.
Conversely, values above 2 in that screening indicate that the effect
of the ASO is protective.
Hits Detection Based on a LMM
The previous approach was not able to deal with the variance produced
by the fact that each plate was run in triplicate. Therefore, we comple-
mented the B score approach with another one based on a LMM:
xrcpik = m+Rr +Cc +gp +ai + ercpik:
In this equation, xrcpik is the measurement value of the k-th biological
replicate of the i-th compound sample in row r, column c, and plate p.
m is the overall average across all measurements. Rr and Cc are row
and column fixed effects, respectively. ai is the random effect for
the i-th sample, which accounts for inter-sample variation. gp is the
random effect for the p-th plate, which accounts for inter-plate vari-
ation. ercpik is a random-error variable, that accounts for the vari-
ability inherent to the sample. The model assumes that ai, gp and
ercpik are Gaussian variables with mean 0 and s2a ; s
2
g s
2
e variances,
respectively. Therefore, the model accounts for positional effects
through the inclusion of row and column fixed effects and adds in-
ter-plate variability. The model can easily be extended to include
specific plate positional biases by the inclusion of a random effect
that interacts with row and column fixed effects.
As in this approach ai is the element of interest. The BLUP
46 (the best
linear unbiased predictor of these random effects) of aican be used to
catch samples that significantly deviate from the overall adjusted
average. Because the experimental design includes biological tripli-
cates, the model takes advantage of this by including all triplicates,
instead of summarizing them, and therefore gains statistical power.
In this approach, the sample outliers, the putative hits, are summa-
rized in a single value given by the BLUPs.ROS Quantification
Subsets of miRNA-ASOs were selected to analyze their effect on the
ROS production that normally accompanies neuronal damage.
miRNA-ASOs were transfected in triplicate, in six independent bio-
logical replicates. After 24 h, half of them were treated with 3 mM
www.moleculartherapy.orgMPP+. CellROX Deep Red Reagent (Molecular Probes) was used to
measure ROS production, and CyQUANT Direct Cell Proliferation
Assay (Invitrogen) was used to normalize ROS levels by the
number of cells. After the transfection (48 h), with or without treat-
ment with MPP+ (24 h), cells were treated with CellROX Deep Red
Reagent at 5 mM and incubated for 30 minutes at 37C, and
fluorescence was measured at 640/665 nm. Afterward, the same cells
were treated with CyQUANT Direct Cell Proliferation Assay.
CyQUANT (15 mL; 10 solution) was added to each well, the cells
were incubated for 2 h at 37C, and fluorescence was measured at
485/535 nm.
Fold change measures were used in order to assess whether the sub-
sets of miRNA-ASOs had collective effects in the production of ROS,
by comparing each subset of miRNA-ASOs affecting cell viability
with the mock-transfected condition. The approach used was again
a LMM, as it allowed accounting for the different sources of variability
that the experiment involved. It also allowed the attainment of a
normalized fold change (FC). The formula used was:
log

xjpik

= m+ bj +gp +ai + ercpik:
In this equation, xjpik is the measurement value of the k-th technical
replicate of the i-th miRNA-ASO in the p-th plate and the j-th group.
If the miRNA-ASO affects cell viability, j = 1; if it does not, j = 0. m is
the overall average across all measurements, bj is the group fixed ef-
fect, ai is the random effect for the i-th miRNA-ASO (accounting for
inter-miRNA-ASO variation), gp is the random effect for the p-th
plate (accounting for inter-plate variation), and ejpik is a random-error
variable (accounting for the intra-sample variability). The model as-
sumes that ai, gp; and ercpik are Gaussian variables with mean 0 and
s2a ; s
2
g; and s
2
e variances, respectively. Under the assumptions of
this LMM, the adjusted FC is obtained as FC = expðbÞ.Determination of Mitochondrial Functionality
To determine mitochondrial activity, we used the MitoTracker Deep
Red probe (Invitrogen), which passively diffuses across plasma
membranes and accumulates in active mitochondria. After the
transfection (48 h), the cells were treated with MitoTracker Deep
Red reagent at 0.1 mM and incubated for 1 h at 37C, and fluores-
cence was measured at 579/599 nm. Carbonylcyanide chlorophenyl-
hydrazone (CCCP) 5 mM was used as the positive control for the
mitochondria depolarization. The Kruskal-Wallis test was used to
compare all conditions, followed by the Mann-Whitney U test
with Bonferroni’s post hoc correction. p < 0.05 was considered sta-
tistically significant.
RNA Extraction and Small RNA Sequencing
Total RNAwas isolated from cells, 24 h after treatment withMPP+ or
a control solution, in four independent biological replicates. After the
medium was removed from cells treated with MPP+ for 24 h, the
plates were washed once in PBS and immediately frozen at 80C.
Total RNA was isolated with the miRNeasy kit (QIAGEN), according
to the manufacturer’s instructions.RNA integrity was evaluated with Bioanalyzer 2100 (Applied Bio-
systems), with RNA integrity number (RIN) > 9 in all samples. Small
RNA (sRNA) indexed libraries for sequencing were prepared from
1 mg of total RNA, using the Trueseq kit (Illumina), according to
the manufacturer’s specifications. Library preparation for control
and MPP+-treated cells was performed in parallel, and indexed sam-
ples were sequenced in a single lane in a HiSeq2000 (Illumina). The
reads generated were 50 nt long.
sRNA Profiling
Reads were trimmed to 36 nt and ligation adapters removed using the
adrec.jar program from the seqBuster suite.47 Sequences were map-
ped to the hg19 genome. sRNA processing, mapping, and annotation
were performed using the SeqBuster and SeqCluster tools, as
described in prior studies.47,48 We used DESeq2 for differential
expression analysis and log2 transformation of the count data. We
followed the standard steps for the analysis: load count matrix, esti-
mation of dispersion, and negative binomial Wald test, with outlier
removal using DESeq2 functions.49
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Plate positional effects in B score determinations 
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Supplemental Figure 1. Hit map showing plate positional effects in cell viability well 
assays. In A.  each cell represents the estimated row effect for the specific plate. In B. 
each cell represents the estimated column effect for the specific plate. Positional effects 
are estimated from median polish of 2-way tables. Rows/columns closer within a plate 
cluster together. An analogous analysis considering the plate order in the FHTS did not 
reveal any specific pattern. 
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Supplemental Figure 2. Hits distribution across different B scores values. Distribution is 
evaluated for non-expressed (black bars) and expressed (light grey bars) sncRNAs in SH-
SY5Y. We consider expressed miRNA as those showing above 1 count, according to the 
sequencing data. 
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Supplemental Figure 3. ROS levels in mock-transfected cells and cells transfected with a 
sncRNA inhibitor with no effect in cell viability (C-) and a sncRNA inhibitor that decreases cell 
viability. Results are shown under basal conditions (-) and following treatment with MPP+ 3 
mM. In each replicate ROS levels are represented by a dot and expressed relative to a 
control, mock-transfected well. Statistically, differences between conditions are determined 
using linear mixed effects models, were experimental conditions to be compared are included 
in the model as fixed affects and plates are included as random effects to account for 
between plate variability. A Bonferroni correction was applied to account for multiple 
comparisons (number of comparisons = 9). Significant differences are found between MPP+-
treatment and basal conditions, in each experimental condition (Mock, C- and C+)  (*, P < 
0.001), and in C+ versus Mock and C- under basal conditions and after exposure to MPP+ (+, 
P < 0.001).	
 
Supplemental Figure 4. Correlation analysis (Pearson correlation coefficient with 
95% CI) between cell viability (B-scores) and ROS levels of sncRNA –ASOs in basal 
conditions (A) and after exposure to MPP+, 3 mM (B). 
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B score 
sncRNA1 GAGGAAUGAUGACAAGAAAAGGC
sncRNA2 UUAGGUCGCUGGUUCGUUUCCG
sncRNA3 GGUCCCAUGGUGUAAUGGUUAGCA
sncRNA4 GGGGGUGUAGCUCAGUGGUAGA
sncRNA5  UGGUCGUGGUUGUAGUCCGUG
sncRNA6 UUAGACGGGCUCACAUCACCC
sncRNA7 CAUGAUAUUUGUGGAAAUUCUGA
sncRNA8 GGAGGUGAUGAACUGUCUGAGC
sncRNA9 GGGUUCGAUUCCCGGUCAGGGA
sncRNA10 AUAACCUGAAGAAAAAUAAGUA
sncRNA11 AGUGAGUGUUGAGACUCUGGG
sncRNA12 AUGCAGUGUGGAACACAAUGA
sncRNA13 UGAGCAUGUAGACAAAGGUAAC
sncRNA14 CAGGUCCCUGUUCGGGCGCCA
sncRNA15 AGGGAUUGUGGGUUCGGGUCCC
sncRNA16 CAGUCGGUAGAGCAUGAGAC
sncRNA17 AAAGACUUUUUCUCUGACCA
sncRNA18 GUCUCUGUGGCGCAAUGGAC
sncRNA19 CCUCAGUAAGUUGCAAUACUUA
sncRNA20 UGAGCUUUUUAACCCUGAGCAA
sncRNA21 GUUUCCGUAGUGUAGCGGUUAU
sncRNA22 UGGCCAAGGAUGAGAACUCUAA
sncRNA23 GGCCGUGAUCGUAUAGUGGUUA
sncRNA24 CACCCUGAACGCGCCCGA
sncRNA25 UAAAGAUUAAGAGAACCAACAC
sncRNA26 GGUGCAAUUUUUGGAAAAAUG
sncRNA27 UUUGCGGGAUGCCUGGGAGUU
sncRNA28 AAGAUAAAAUUUGAAAUCUGG
sncRNA29 UUCCGUAGUGUAGUGGUUAUC
sncRNA30 GGCUGGUCCGAGUGCAGUGGU
sncRNA31 CUCCCACUGCUUCACUUGACUA
sncRNA32 GUCAGGAUGGCCGAGCGGUCU
sncRNA33 AUGGAUUUUUGGAGCAGGGAGA
sncRNA34 UCGACCUGGUAUUGCAGUACCU
sncRNA35 GCCGGGCGCGGUGGCGCGUGCC
sncRNA36 GGUAAAAUGGCUGAGUGAAGCA
sncRNA37 GCUAACUUUGACUGGCUU
sncRNA38 GGGUUCGUUUCCCGGUCAGG
sncRNA39 AGCAGAGUGGCGCAGCGGAAGC
sncRNA40 ACCGGGUGCUGUAGGCUUA
sncRNA41 GGUAAAAUAGCUGAGUGAAGCA
sncRNA42 GUUUCCGUAGUGUAGUGGUUAU
sncRNA43 AAUCAUGAAGAGAUGUACUAU
sncRNA44 GUAGUCGUGGCCGAGUGGUUAAG
sncRNA45 GAGACUCUGAAAUCUGAUU
sncRNA46 UUCAAGUGAUGUCAUCUUACU
sncRNA47 CUCAAAAGGAUUAUGCUGAGGCC
sncRNA48 GUUAAAGACUUUUUCUCUGACC
sncRNA49 GGTATAGCTCAGTGGTAGAGCA
sncRNA50 AUUGGAAGACACUCUGCGACAGUG
Table S1. Small RNA sequences targeted by 
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